Mounjaro is one of the most popular diabetes and weight loss drugs, and while you can't buy Mounjaro stock, you can invest in the company that makes it. Pharmaceutical company Eli Lilly (LLY 0.48%) manufactures and distributes Mounjaro, along with over 50 other medicines to treat a range of conditions.
In this guide on how to invest in Mounjaro, we'll go into more detail about the medication and its parent company. You'll also learn about your investment options and what to expect from the healthcare sector.
Is it publicly traded?
Is Mounjaro publicly traded?
Mounjaro isn't publicly traded on the stock market, but its parent company, Eli Lilly, is. Eli Lilly went public in 1952 and is now one of the largest companies in the world.
Will it IPO?
When will Mounjaro IPO?
Since Mounjaro is a single product in Eli Lilly's portfolio, there won't be an initial public offering (IPO) for it. Some companies spin off certain divisions, which is theoretically possible with Mounjaro and similar products. But it's highly unlikely that Eli Lilly would do that, given that Mounjaro was its bestselling product in 2024.
How to invest
How to buy Mounjaro stock
You can't buy Mounjaro stock directly. But you can make an indirect investment, either by buying shares in the company that makes it or by investing in other pharmaceutical stocks. Here are three options to consider.
Eli Lilly
The closest you can get to investing in Mounjaro is buying Eli Lilly. The pharmaceutical giant started selling Mounjaro, which is the brand name for tirzepatide, in 2022. While Mounjaro is arguably now Eli Lilly's flagship product, it's part of a broad portfolio that also includes type 2 diabetes treatment Trulicity, cancer treatments in Alimta and Cyramza, and Cymbalta, which is used to treat major depressive disorder.
Novo Nordisk
If you'd like to invest in weight loss drugs, Novo Nordisk (NVO 2.15%) is another good option. This Danish company is the manufacturer of Ozempic and Wegovy. It has two business segments: Diabetes and Obesity Care and Rare Disease.
Johnson & Johnson
Johnson & Johnson (JNJ 0.03%) is a fairly safe healthcare company to invest in, and it pays a high dividend. Its two business segments are Innovative Medicine, which manufactures pharmaceutical products, and MedTech, which makes orthopedics, surgical and interventional solutions, and vision care products.
How to invest
Once you've decided which companies you like, here's how to invest in stocks step by step.
- Open your brokerage app: Log into your brokerage account where you handle your investments.
- Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Profitability
Is Mounjaro profitable?
Eli Lilly is a profitable company, and Mounjaro is its biggest revenue driver. Mounjaro accounted for $11.5 billion of revenue in 2024, about a quarter of Eli Lilly's total revenue of $45 billion. Net income was $10.6 billion, more than doubling year over year.
Should I invest?
Should I invest in Mounjaro?
Mounjaro and other weight loss drugs are well worth considering as an investment. Even though you can't invest purely in weight loss medication, you can buy stocks with exposure to that valuable market.
There's certainly a need for this type of treatment. Obesity is a worldwide issue that has become more and more common. Adult obesity has doubled since 1990, and adolescent obesity has quadrupled, according to the World Health Organization (WHO). WHO also reports that 1 in 8 people in the world were living with obesity as of 2022.
While the anti-obesity market has grown significantly already, analysts project that it could be worth much more by the end of the decade. The market has a value of about $28 billion as of 2025, according to analysts at Goldman Sachs (GS -0.74%), and is projected to grow to $95 billion in 2030. In addition, BMO (BMO -0.2%) Capital Markets estimates that sales of weight loss drugs could reach $150 billion by 2033.
As far as potential challenges go, the current crop of weight loss drugmakers will likely have more competition in the future as other companies in the biotech and pharmaceutical industries try to get a piece of the market. And even though the projections look promising, those are just projections. We can't be sure this rapid growth will continue. Still, healthcare companies tend to be reasonably safe investments, so they don't add too much risk to your portfolio.
ETFs
ETFs with exposure to Mounjaro
There are hundreds of exchange-traded funds (ETFs) that hold Eli Lilly and, in turn, provide exposure to Mounjaro. If you want to invest in a diverse mix of healthcare or pharmaceutical stocks, an ETF could be a smart way to go. Here are a few options:
- The Vanguard Healthcare ETF (VHT -0.22%) tracks an index of stocks in the healthcare sector. While it has hundreds of stocks, Eli Lilly is its largest holding. Like just about every Vanguard fund, this ETF has a low expense ratio (0.09%, or $9 per year for every $1,000 invested).
- The iShares U.S. Healthcare ETF (IYH -0.31%) provides exposure to U.S. healthcare equipment and services, pharmaceuticals, and biotech companies. Eli Lilly is one of its biggest holdings, as is Johnson & Johnson. The ETF has a 0.39% expense ratio.
- The Vanguard Dividend Appreciation ETF (VIG -0.4%) invests in large-cap stocks with a track record of growing their dividends year after year, so it's well-suited for passive income investors. It's not healthcare-focused, but healthcare companies make up a sizable portion of its holdings. The Vanguard ETF has a 0.05% expense ratio.
Related investing topics
The bottom line on Mounjaro
Weight loss drugs have been an exciting and profitable recent development for pharmaceutical companies. If you're hoping to invest, the first option would be to buy the company that makes the treatment you most like. For anyone interested in Mounjaro stock, that'd be Eli Lilly.
FAQ
Investing in Mounjaro FAQ
How do I buy Eli Lilly stock?
To buy Eli Lilly stock, log into your brokerage account and search for its ticker: LLY. Enter your order details, including the number of shares you want to buy and the order type. When you're ready, submit your order.
How do I buy Mounjaro stock?
You can't buy Mounjaro stock, because Mounjaro is a product manufactured and sold by Eli Lilly. You could invest in Eli Lilly to get exposure to Mounjaro since it's the pharmaceutical company's bestselling product.
Is Eli Lilly a good investment?
Eli Lilly is generally considered a good investment. It has a large portfolio of popular pharmaceutical products, it's profitable, and it has been in business for about 150 years.
Should I invest in Eli Lilly?
Consider buying Eli Lilly stock if you want to invest in weight loss drugs or if you're looking for a quality dividend stock. While Eli Lilly has a variety of products, weight loss medication has been driving its recent growth.
